In pursuit of new anti-angiogenic therapies for cancer treatment

被引:12
作者
Cai, Jun [1 ]
Han, Song [2 ]
Qing, Ruan [1 ]
Liao, Daiqing [1 ]
Law, Brian [3 ]
Boulton, Michael E. [1 ]
机构
[1] Univ Florida, Dept Anat & Cell Biol, Gainesville, FL 32610 USA
[2] Univ Florida, Dept Surg, Gainesville, FL 32610 USA
[3] Univ Florida, Dept Pharmacol & Therapeut, Gainesville, FL 32610 USA
来源
FRONTIERS IN BIOSCIENCE-LANDMARK | 2011年 / 16卷
关键词
Tumor Angiogenesis; Anti-Angiogenic Therapy; Vasculature; Endothelial Cells; Review; ENDOTHELIAL GROWTH-FACTOR; TUMOR ANGIOGENESIS; ANTIANGIOGENIC THERAPY; VASCULAR-PERMEABILITY; BEVACIZUMAB; SORAFENIB; SUNITINIB; HYPOXIA; VEGF; CHEMOTHERAPY;
D O I
10.2741/3721
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
Despite advances in surgery, radiation therapy, and chemotherapy, patients with cancer have a poor prognosis. Sustained aberrant tumor angiogenesis and metastasis is a major obstacle for effective cancer treatment. Just a few years ago, few would argue that one of the key success stories of the modern cancer medicine were the anti-angiogenic drugs targeting the vascular endothelial growth factor (VEGF) signaling pathway approved by FDA. This initial success inspired many researchers to search for new anti-angiogenic targets and drugs with the hope that one day, anti-angiogenic therapy might really become the panacea for cancer patients. Unfortunately, the limited clinical benefits achieved with anti-angiogenic drugs conflicts with the widely accepted notion that angiogenesis is a key event in tumor progression. Emerging data indicate that unique characteristics of the tumor vasculature within the tumor microenvironment may hold the key for success of anti-angiogenic therapy. In particular, the molecular and cellular alterations that sustain aberrant tumor angiogenesis in the face of angiogenic inhibitors represents novel targets for rationally designing and improving current anti-angiogenic strategies.
引用
收藏
页码:803 / 814
页数:12
相关论文
共 101 条
[1]
Abrams TJ, 2003, MOL CANCER THER, V2, P1011
[2]
Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon Cancer [J].
Allegra, Carmen J. ;
Yothers, Greg ;
O'Connell, Michael J. ;
Sharif, Saima ;
Colangelo, Linda H. ;
Lopa, Samia H. ;
Petrelli, Nicholas J. ;
Goldberg, Richard M. ;
Atkins, James N. ;
Seay, Thomas E. ;
Fehrenbacher, Louis ;
O'Reilly, Seamus ;
Chu, Luis ;
Azar, Catherine A. ;
Wolmark, Norman .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (20) :3385-3390
[3]
Baish JW, 2000, CANCER RES, V60, P3683
[4]
Bevacizumab and oxaliplatin-based chemotherapy in metastatic colorectal cancer [J].
Beatty, Gregory L. ;
Giantonio, Bruce J. .
EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (05) :683-688
[5]
Raf: A strategic target for therapeutic development against cancer [J].
Beeram, M ;
Patnaik, A ;
Rowinsky, EK .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (27) :6771-6790
[6]
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors [J].
Bergers, G ;
Song, S ;
Meyer-Morse, N ;
Bergsland, E ;
Hanahan, D .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (09) :1287-1295
[7]
Modes of resistance to anti-angiogenic therapy [J].
Bergers, Gabriele ;
Hanahan, Douglas .
NATURE REVIEWS CANCER, 2008, 8 (08) :592-603
[8]
Phase 1b Study of Motesanib, an Oral Angiogenesis Inhibitor, in Combination with Carboplatin/Paclitaxel and/or Panitumumab for the Treatment of Advanced Non-Small Cell Lung Cancer [J].
Blumenschein, George R., Jr. ;
Reckamp, Karen ;
Stephenson, G. Joe ;
O'Rourke, Timothy ;
Gladish, Gregory ;
McGreivy, Jesse ;
Sun, Yu-Nien ;
Ye, Yining ;
Parson, Mandy ;
Sandler, Alan .
CLINICAL CANCER RESEARCH, 2010, 16 (01) :279-290
[9]
BRIZEL DM, 2004, CANCER RES, V64, P6010
[10]
Exposure to nuclear antigens contributes to the induction of humoral autoimmunity during tumour necrosis factor alpha blockade [J].
Cantaert, T. ;
De Rycke, L. ;
Mavragani, C. P. ;
Wijbrandts, C. A. ;
Niewold, T. B. ;
Niers, T. ;
Vandooren, B. ;
Veys, E. M. ;
Richel, D. ;
Tak, P. P. ;
Crow, M. K. ;
Baeten, D. .
ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (06) :1022-1029